An endothelial-specific TIE2-L914F mouse model reveals cellular mechanisms of venous malformation progression and recapitulates the patient's response to targeted therapy
- 1Cincinnati Children's Hospital Medical Center
Abstract
TIE2 p.L914F is the most common driver mutation of sporadic venous malformation (VM), a disease characterized by massively enlarged veins. The study of the molecular and cellular mechanisms contributing to TIE2-driven VM has been hindered by the lack of a genetic in vivo model. We generated a mouse system in which TIE2L914F is expressed postnatally in endothelial cells (EC). Mutant mice develop visible lesions with dilated veins with irregular smooth muscle cell coverage, histologically mimicking patients VM. With the use of an mCherry reporter we demonstrate that lesions form within the venous vasculature, and mutant ECs undergo clonal expansion fueled by a biphasic mechanism consisting of an early burst of proliferation followed by cell size increase. Targeted treatment with rapamycin partially reduces lesion growth by targeting increased proliferation and prolongs mouse survival, demonstrating this genetic murine model recapitulates the patients therapeutic response. Together, these findings provide new cellular and mechanistic insights into TIE2 p.L914F-driven venous malformation and establish a genetic platform for preclinical therapeutic studies.
Related
- Lysosomal Dysfunction-Mediated IgG Accumulation Promotes Endothelial Senescence and Lesion Progression in Cerebral Cavernous Malformations
- Multi‐omics integration and machine learning identify an ACKR1+ endothelial cell‐based lactate‐immune signature associated with carotid plaque vulnerability and progression
- Ligand-specific endothelial Notch signaling coordinates brain pericyte specification and expansion
- Food-Derived Bioactives and the Endothelial Glycocalyx: Chemical Determinants, Molecular Mechanisms, and Translational Evidence
- The role and mechanism of endothelial cell-specific molecule-1 in respiratory diseases.
BibTeX
@misc{bischoff2026endothelialspecific,
title = {{An endothelial-specific TIE2-L914F mouse model reveals cellular mechanisms of venous malformation progression and recapitulates the patient's response to targeted therapy}},
author = {L. J. Bischoff and S. Schrenk and A. Barney and K. Soroko and C. Sherpa and M. Simons and E. Boscolo},
howpublished = {bioRxiv},
year = {2026},
month = oct,
doi = {10.64898/2026.10.29.762550},
url = {https://www.biorxiv.org/content/10.64898/2026.10.29.762550v1},
note = {CC BY-NC},
}
RIS
TY - UNPB
TI - An endothelial-specific TIE2-L914F mouse model reveals cellular mechanisms of venous malformation progression and recapitulates the patient's response to targeted therapy
AU - L. J. Bischoff
AU - S. Schrenk
AU - A. Barney
AU - K. Soroko
AU - C. Sherpa
AU - M. Simons
AU - E. Boscolo
PY - 2026
DA - 2026/10/29
PB - bioRxiv
DO - 10.64898/2026.10.29.762550
UR - https://www.biorxiv.org/content/10.64898/2026.10.29.762550v1
AB - TIE2 p.L914F is the most common driver mutation of sporadic venous malformation (VM), a disease characterized by massively enlarged veins. The study of the molecular and cellular mechanisms contributing to TIE2-driven VM has been hindered by the lack of a genetic in vivo model. We generated a mouse system in which TIE2L914F is expressed postnatally in endothelial cells (EC). Mutant mice develop visible lesions with dilated veins with irregular smooth muscle cell coverage, histologically mimicking patients VM. With the use of an mCherry reporter we demonstrate that lesions form within the venous vasculature, and mutant ECs undergo clonal expansion fueled by a biphasic mechanism consisting of an early burst of proliferation followed by cell size increase. Targeted treatment with rapamycin partially reduces lesion growth by targeting increased proliferation and prolongs mouse survival, demonstrating this genetic murine model recapitulates the patients therapeutic response. Together, these findings provide new cellular and mechanistic insights into TIE2 p.L914F-driven venous malformation and establish a genetic platform for preclinical therapeutic studies.
ER -